Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.

Samuel L WashingtonJohn NeuhausMaxwell V MengSima P Porten

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2019)

If we are not delivering evidence-based care due to these biases (after accounting for access and biology), then it is expected that patients will experience inferior outcomes.

Keyphrases

muscle invasive bladder cancer
end stage renal disease
healthcare
newly diagnosed
ejection fraction
chronic kidney disease
palliative care
prognostic factors
quality improvement
metabolic syndrome
adipose tissue
skeletal muscle
pain management
replacement therapy